Aligos Therapeutics reported a net income of $43.1 million for the first quarter of 2025, a significant shift from a net loss of $34.9 million in the prior year period. This positive net income was primarily driven by a non-cash gain of $61.5 million from the remeasurement of 2023 common warrants. Research and development (R&D) expenses decreased to $14.5 million from $16.4 million year-over-year, mainly due to reduced third-party clinical trial expenses.
As of March 31, 2025, the company's cash, cash equivalents, and investments totaled $137.9 million. This financial position is expected to provide sufficient funding for planned operations into the second half of 2026. The company's cash runway was bolstered by a recent $105 million private placement.
Aligos announced that its Phase 2 study of ALG-000184 for chronic hepatitis B virus infection is on track to begin dosing by mid-2025, following positive correspondence with the FDA. The company also continues partnering discussions for ALG-055009 with multinational pharmaceutical companies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.